Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Alnylam Pharmaceuticals ALNY is a commercial-stage company that currently markets four drugs. The company first received regulatory approval in 2018 for Onpattro to treat adult patients with hereditary transthyretin-mediated (hATTR) amyloidosis. Subsequently, ALNY received approval for Givlaari (acute hepatic porphyria), Oxlumo (primary hyperoxaluria type 1) and Amvuttra (polyneuropathy of hATTR amyloidosis).

In 2025, Alnylam received approval in the United States and the EU for the label expansion of Amvuttra to treat ATTR amyloidosis with cardiomyopathy (ATTR-CM) in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits. Following the label expansion, Amvuttra became the first and only RNAi therapeutic approved in the United States and the EU for both ATTR-CM and hATTR-PN in adults, marking a significant milestone.

Currently, Amvuttra (vutrisiran), its newest drug, is Alnylam's primary top-line driver. The drug generated $889.9 million in global sales in the first quarter of 2026, representing 187% year-over-year growth. The figure accounted for 76% of Alnylam's total revenues generated in the quarter. The drug's solid uptake has been driven by increased patient demand, mainly in ATTR-CM patients in the United States, as well as several patients switching from Onpattro.

This label expansion is expected to continue boosting Amvuttra sales in the quarters ahead. Alnylam also expects approvals for Amvuttra for the ATTR-CM indication in other geographies this year. This will expand the eligible patient population for the drug, driving substantial growth for the company in the future.

ALNY's Competition in the Market for ATTR Treatments

Alnylam's Amvuttra faces notable competition in the ATTR-CM market from Pfizer's PFE Vyndaqel/Vyndamax (tafamidis) and BridgeBio's BBIO Attruby (acoramidis), both of which are already approved for this indication. While Amvuttra is positioned with a differentiated clinical profile, Pfizer's and BridgeBio's therapies carry the advantage of oral administration and comparatively lower list prices in the United States. These factors could influence prescribing decisions and pose challenges to Alnylam's competitive positioning in this space.

Vyndaqel is one of the key in-line products that has driven improvement in Pfizer's revenues in the first quarter of 2026. Global Vyndaqel family revenues of $1.6 billion rose 8% year over year in the quarter, primarily driven by international growth on the back of higher demand due to increases in diagnosis and treatment rates. Pfizer's Vyndaqel family includes global revenues from Vyndaqel as well as revenues for Vyndamax in the United States and Vynmac in Japan.

Story Continues

Approved in late 2024, Attruby is BridgeBio's only marketed product. The drug generated sales worth $180.6 million in the first quarter of 2026, up significantly year over year, driven by solid uptake. BridgeBio is also currently evaluating acoramidis for the prevention of early-stage variant transthyretin amyloidosis in a late-stage study.

ALNY's Stock Price, Valuation and Estimates

Shares of Alnylam have plunged 27.3% so far this year compared with the industry's 4% decline. The stock has also underperformed the sector and the S&P 500 index during the same time frame, as seen in the chart below.

ALNY Stock Price MovementZacks Investment Research

Image Source: Zacks Investment Research

From a valuation standpoint, Alnylam stock is expensive. Going by the price/sales ratio, the company's shares currently trade at 9.33 trailing 12-month sales per share, higher than 2.25 for the industry. However, the stock is also trading much below its five-year mean of 18.40.

ALNY Stock ValuationZacks Investment Research

Image Source: Zacks Investment Research

Estimates for Alnylam's 2026 earnings have improved from $9.13 to $9.22 per share in the past 60 days, while the estimates for 2027 earnings have deteriorated from $14.59 to $13.68 over the same timeframe.

ALNY Estimate MovementZacks Investment Research

Image Source: Zacks Investment Research

Alnylam currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Alnylam Pharmaceuticals, Inc. (ALNY) : Free Stock Analysis Report

Pfizer Inc. (PFE) : Free Stock Analysis Report

BridgeBio Pharma, Inc. (BBIO) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

CAMBRIDGE, Mass., June 12, 2026--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it plans to host its 10th series of "RNAi Roundtable" webinars over the coming months. The series will offer presentations from Alnylam scientists and physicians who will review recent progress in a selection of the Company’s pipeline programs, as well as medical thought leaders who will provide their perspectives on unmet clinical needs. Each event will be webcast live on the Investors section of the Company’s website at investors.alnylam.com/events, and a replay will be posted on the Alnylam website approximately three hours after each event.

The 2026 RNAi Roundtable schedule is as follows:

ALN-6400: Targeting Plasminogen to Address a Wide Range of Bleeding Disorders

Thursday, June 25, 11:00 am ET Zilebesiran: Targeting Angiotensinogen to Achieve Continuous Control of Blood Pressure

Thursday, September 17, 10:30 am ET ALN-HTT02: Targeting Exon 1 of Huntingtin Gene to Reduce Progression of Huntington’s Disease

Monday, October 26, 10:00 am ET

Alnylam’s leadership in RNAi therapeutics is underpinned by a broad and rapidly advancing pipeline spanning multiple therapeutic areas and stages of development. The Company is focused on its Alnylam 2030 goals, including driving Growth Through Sustainable Innovation, by advancing an industry-leading pipeline of RNAi therapeutics designed to prevent, halt, or reverse disease. Specifically, the Company plans to achieve over 40 clinical programs by 2030—from over 25 today—and to continue expanding into new tissues, while harnessing the latest AI technologies to accelerate and optimize its discovery platform. Alnylam is investing meaningfully in R&D to extend the reach of RNAi and deliver multiple new transformative medicines for patients with serious diseases and high unmet need.

About Alnylam Pharmaceuticals Alnylam (Nasdaq: ALNY) is a leading global biopharmaceutical company and the pioneer of the RNA interference (RNAi) revolution. The Company is focused on developing transformative therapies with the potential to prevent, halt, or reverse disease. For more than two decades, Alnylam has advanced the Nobel-Prize-winning science of RNAi, delivering critical breakthroughs and six approved medicines. Alnylam has medicines available in more than 70 countries and a rapidly expanding and robust pipeline, in addition to consistently being recognized as an exceptional workplace and socially responsible organization. The Company is executing on its Alnylam 2030 strategy to accelerate innovation and scale impact to transform human health. For more information, please visit www.alnylam.com or follow Alnylam on X, LinkedIn, Facebook, Instagram, or YouTube.

Story Continues

Forward Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than historical statements of fact regarding Alnylam’s expectations, beliefs, goals, plans or prospects including, without limitation, statements regarding Alnylam’s ability to achieve the goals in its Alnylam 2030 strategy, including to drive growth through innovation; the potential to expand its pipeline to over 40 clinical programs by 2030; the potential to expand into new tissues; the potential to utilize AI technologies to accelerate and optimize its discovery platform; and the potential to deliver multiple new transformative medicines for patients should be considered forward-looking statements. Actual results and future plans may differ materially from those indicated by these forward-looking statements as a result of various important risks, uncertainties and other factors, including, without limitation, risks and uncertainties relating to: Alnylam’s ability to successfully execute on its Alnylam 2030 strategy; Alnylam’s ability to successfully launch, market and sell Alnylam’s approved products globally, including AMVUTTRA; Alnylam’s ability to discover and develop novel drug candidates and delivery approaches and successfully demonstrate the efficacy and safety of its product candidates; the pre-clinical and clinical results for Alnylam’s product candidates; actions or advice of regulatory agencies and Alnylam’s ability to obtain and maintain regulatory approval for its product candidates, as well as favorable pricing and reimbursement; delays, interruptions or failures in the manufacture and supply of Alnylam’s marketed products or its product candidates; obtaining, maintaining and protecting intellectual property; Alnylam’s ability to manage its growth and operating expenses through disciplined investment in operations; Alnylam’s ability to maintain strategic business collaborations; Alnylam’s dependence on third parties for the development and commercialization of certain products, including Roche, Novartis, Sanofi, and Regeneron; the outcome of litigation and government investigations; the risk of future litigation and government investigations; and unexpected expenditures; as well as those risks and uncertainties more fully discussed in the "Risk Factors" filed with Alnylam’s 2025 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC), as may be updated from time to time in Alnylam’s subsequent Quarterly Reports on Form 10-Q, and in other filings that Alnylam makes with the SEC. In addition, any forward-looking statements represent Alnylam’s views only as of today and should not be relied upon as representing its views as of any subsequent date. Alnylam explicitly disclaims any obligation, except to the extent required by law, to update any forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260612239247/en/

Contacts

Alnylam Pharmaceuticals, Inc. Christine Akinc (Investors and Media) 617-682-4340

Josh Brodsky (Investors) 617-551-8276

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Industry veterans from Sunrise BioVentures to provide strategic and operational support as the company advances its JUN_01 siRNA cardiometabolism program toward Phase 1 clinical trials and progresses its RESET Platform pipeline

SAN FRANCISCO, June 10, 2026--(BUSINESS WIRE)--Junevity, a biotechnology company on a mission to extend lifespan and healthspan with siRNA therapeutics, today announced a partnership with Sunrise BioVentures ("Sunrise"), a leading RNA therapeutics accelerator. Sunrise leadership comprises RNA veterans Andrew Fraley, Ph.D., Rachel Meyers, Ph.D., Stuart Milstein, Ph.D., and Laurence Reid, Ph.D., who focus on the rapid advancement of novel oligonucleotide therapeutics and platforms. The Sunrise team brings decades of experience spanning the discovery and development of siRNA and other nucleic acid therapeutics at pioneering companies, including Alnylam Pharmaceuticals, Korro Bio, Judo Bio and Decibel Therapeutics.

The Sunrise team will provide active, strategic and operational guidance across Junevity's siRNA development, preclinical validation, pipeline strategy and business development as the company advances its lead candidate, JUN_01, toward Phase 1 clinical trials for cardiovascular risk in type 2 diabetes, anticipated to begin in the fourth quarter of 2026. JUN_01 is the first known siRNA candidate designed to reprogram metabolism to a healthier state, with preclinical studies demonstrating reduced inflammation, reduced cardiovascular risk markers, robust HbA1c reduction and improved insulin sensitivity, with dosing once every six to twelve months.

"As we prepare to bring JUN_01 into the clinic and expand our pipeline with the RESET Platform, we are assembling a team with deep, proven expertise in getting siRNA therapeutics to patients," said John Hoekman, Ph.D., co-founder and CEO of Junevity. "Rachel, Stuart, Laurence and Andrew have collectively helped build the oligonucleotide therapeutics field from its earliest days including multiple products in the clinic and FDA approvals at Alnylam. Their guidance will be invaluable as we advance JUN_01 and grow our pipeline of cell reprogramming therapeutics for longevity."

"In forming Sunrise BioVentures, we wanted to use our extensive experience developing RNA therapeutics to help a variety of startups accelerate their efforts to bring new RNA-driven modalities to market, and we are thrilled to announce one of our first collaborations as advisors to Junevity," said Rachel Meyers, Managing Partner at Sunrise. "Junevity has built an exciting siRNA pipeline in a short time with strong scientific foundations, the RESET Platform and very promising data. We take on this strategic role based on our belief in the Junevity leadership team and the potential impact of JUN_01 and their pipeline."

Story Continues

The appointments reinforce Junevity's momentum following its $20 million financing, led by Goldcrest Capital and Godfrey Capital, and the publication of its foundational research in Proceedings of the National Academy of Sciences (PNAS) validating that precise modulation of individual transcription factors can reverse core hallmarks of cellular aging and restore tissue function in vivo.

About the Sunrise Partners

Rachel Meyers,Ph.D., is an entrepreneurial scientist and recognized leader in RNA-based medicine with more than 25 years of drug discovery and development experience. She spent over 13 years at Alnylam Pharmaceuticals, ultimately serving as Senior Vice President of Research and RNAi Lead Development, where she played a central role in advancing the company's RNAi therapeutic programs from early discovery through clinical development. Dr. Meyers currently serves on the Board of Directors of Korro Bio and on the Alnylam Scientific Advisory Board, and holds advisory roles at CAMP4 Therapeutics and other biotech companies. She was previously the Founder and Chief Scientific Officer of Faze Medicines, a Third Rock Ventures–spawned biotech company. Dr. Meyers received her Ph.D. from MIT, where she trained with Nobel Laureate Phil Sharp, and completed postdoctoral work at Harvard Medical School.

Stuart Milstein, Ph.D., has nearly two decades of experience in oligonucleotide therapeutics at the intersection of platform innovation and drug development. He currently holds active, strategic roles at Orfonyx Bio and Aerska. Stuart began his career at Alnylam Pharmaceuticals, where he led the RNAi Lead Development group responsible for the optimization of all clinical candidates in the company's pipeline. He contributed to multiple approved products, including Onpattro, the first approved RNAi therapeutic, and initiated the company's efforts in CNS delivery of siRNA. He subsequently served as Vice President of Platform Biology at Korro Bio, where he helped establish the company's RNA editing platform, and as Chief Platform Officer at Senda Biosciences. Dr. Milstein trained as a research fellow at Harvard Medical School and Dana-Farber Cancer Institute.

Laurence Reid, Ph.D., is a biotech entrepreneur, company builder and advisor with 30 years of experience in the pharmaceutical and biotechnology industries. He previously served as CEO of Decibel Therapeutics, leading the company through its acquisition by Regeneron Pharmaceuticals, and as CEO of Warp Drive Bio through its merger with Revolution Medicines. Prior to that, Dr. Reid was Senior Vice President and Chief Business Officer at Alnylam Pharmaceuticals, where he oversaw business development, finance and legal functions and played a leadership role in shaping major alliances, including partnerships with Sanofi/Genzyme, The Medicines Company, and Merck. He currently serves on the boards of KalVista Pharmaceuticals, Metagenomi Therapeutics, and a number of private biotechnology companies. Dr. Reid holds a Ph.D. in Biochemistry from King's College London.

Andrew Fraley, Ph.D., is a serial entrepreneur and scientific innovator with more than 20 years of experience in nucleic acid technologies and therapeutics. He co-founded Judo Bio, where the team is pioneering siRNA delivery to the kidney, and Korro Bio, where he served as founding Chief Technology Officer and helped establish the company's RNA editing platform. Dr. Fraley also co-founded Triplet Therapeutics and Trucode Gene Repair, and previously served as Head of Chemistry at Moderna Therapeutics and as an Entrepreneur-in-Residence at Atlas Venture. He holds a Ph.D. in Bioorganic Chemistry from Boston College and completed postdoctoral research as a Chateaubriand Fellow at Louis Pasteur University.

About Junevity

Junevity is a biotechnology company developing siRNA therapeutics to reset global gene networks for longevity. The Junevity RESET platform is the first to use human disease omics, human genetic linkages and ML/AI to identify novel transcription factor targets and repress them with siRNA therapeutics. Initial programs are in cardiometabolism and neurodegeneration. Based in San Francisco and founded out of UCSF in 2023, Junevity's mission is to increase lifespan and healthspan. Learn more at junevity.com.

About Sunrise BioVentures

Sunrise BioVentures is an accelerator for RNA therapeutics. The Sunrise team works with entrepreneurs and innovators to define and plan the best path from concept of a new RNA-targeting therapeutic toward the demonstration of clinical efficacy. The mission of Sunrise is to deploy the experience of the managing team to develop new RNA therapeutics and advance business models that can generate value for stakeholders through distributed collaboration and efficient use of capital. Contact Sunrise at info@sunrisebioventures.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260610477995/en/

Contacts

Media contact: Tim Ingersoll Linnden Communications tim@linndencom.com

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

The expanded partnership adds Denmark, Finland, Norway and Sweden to GENESIS Pharma’s existing network of thirteen Southeast European markets. It grants rights for the commercialization of Alnylam’s RNAi therapeutics for serious cardiomyopathy conditions and rare genetic diseases.

ATHENS, Greece, June 10, 2026--(BUSINESS WIRE)--GENESIS Pharma, a leading regional biopharma company focused on the commercialization of innovative medicines in Europe, today announced the expansion of its longstanding commercial partnership with Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), the leading RNAi therapeutics company. The extended agreement broadens the geographical reach of the collaboration to include four Nordic markets -Denmark, Finland, Norway, and Sweden- alongside the thirteen markets in Southeast Europe already within the scope of the partnership. GENESIS Pharma shall commercialize a portfolio of RNAi therapeutics for serious cardiomyopathy conditions and rare genetic diseases across this expanded territory.

The partnership, established in 2019 for Southeast Europe, has progressively evolved to encompass a broader portfolio and geographic footprint, covering Greece, Cyprus, Bulgaria, Romania, Slovenia, Croatia, Serbia, Bosnia and Herzegovina, Albania, the Republic of North Macedonia, Montenegro, Malta, and Kosovo. This latest strategic expansion reinforces both companies’ shared commitment to improving patient access to innovative therapies across Europe, particularly in regions where unmet medical needs remain significant.

Norton Oliveira, Senior Vice-President and Head of Partner and Emerging Markets at Alnylam Pharmaceuticals stated: "We are proud of our strong and established partnership with GENESIS Pharma and are delighted to broaden this across the Nordic region. Our commitment is to deliver transformational impact for patients across the world. By working alongside GENESIS Pharma, we can continue to address the needs of even more patients and their families, enabling them to benefit from Alnylam’s innovative RNAi therapeutics."

Constantinos Evripides, Managing Director of GENESIS Pharma stated: "Since 2019, we have been working closely with Alnylam to ensure patient access across Southeast Europe. The expansion in the Nordic countries marks a significant milestone in our partnership and reflects our ongoing efforts to strengthen our European footprint, building on our three-decade legacy and commitment to biotechnology. By combining Alnylam’s pioneering science with our strong regional expertise in bringing innovation closer to patients, we continue to expand our reach and enhance the value we deliver across healthcare systems. We are honored by the trust Alnylam has placed in our company and our people."

Story Continues

About RNAi

RNAi (RNA interference) is a natural cellular process of gene silencing that represents one of the most promising and rapidly advancing frontiers in biology and drug development today.1 Its discovery has been heralded as "a major scientific breakthrough that happens once every decade or so," and was recognized with the award of the 2006 Nobel Prize for Physiology or Medicine.2 By harnessing the natural biological process of RNAi occurring in our cells, a new class of medicines known as RNAi therapeutics is now a reality. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam’s RNAi therapeutic platform, function upstream of today’s medicines by potently silencing messenger RNA (mRNA) – the genetic precursors – that encode for disease-causing or disease pathway proteins, thus preventing them from being made.1 This is a revolutionary approach with the potential to transform the care of patients with genetic and other diseases.

About GENESIS Pharma

GENESIS Pharma is a European biopharma company focused on the commercialization of innovative biopharmaceutical products targeting severe and rare diseases, currently covering 24 countries in Europe. Established in 1997, GENESIS Pharma was among the first pharmaceutical companies in the region to specialize in the marketing, sales and distribution of biopharmaceutical products. GENESIS Pharma maintains a strong portfolio in therapeutic areas with high unmet medical need through long standing strategic alliances with some of the leading global biopharma companies. For more information, please visit www.genesispharma.com and follow us on LinkedIn.

REFERENCES

1 Elbashir SM, Harborth J, Lendeckel W, et al. Nature. 2001;411(6836):494-498.

2 Zamore P. Cell. 2006;127(5):1083-1086.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260610467298/en/

Contacts

For more information, please contact: Natalia Karahaliou, Communications Manager nkarahaliou@genesispharma.com +30 210 87 71 605

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Die beiden neuesten Aufnahmen in den Index waren Marvell Technology und Flex. Die Frage ist, welche Unternehmen als Nächstes in den Index aufgenommen werden könnten. S&P Dow Jones Indices hat eine Reihe von Kriterien, darunter Marktwert, Hauptsitz, Rentabilität und Unternehmensstruktur. Bloom Energy, Astera Labs, Alnylam Pharmaceuticals, Heico Rocket Cos und Reddit scheinen potenzielle Aufnahmen zu sein, da sie unter den größten Unternehmen nach Marktkapitalisierung fallen und die anderen Kriterien erfüllen

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Alnylam Pharmaceuticals (ALNY) hat erneut Aufmerksamkeit gewonnen, nachdem sie eine Kollaboration mit Inceptive Nucleics eingegangen ist, die bis zu US$2b wert sein könnte. Diese Zusammenarbeit konzentriert sich auf die Verwendung generativer AI-Modelle zur Beschleunigung der RNAi-Wirkstoffentdeckung. Der Aktienkurs von Alnylam hat sich in den letzten Tagen um 3,78% erhöht, bleibt jedoch im Jahrzehnt um 24,12% zurück. Die fünfjährige Gesamtrendite des Aktionärs beträgt 85,99%, was auf stärkere langfristige Impulse hinweist.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Große Biotech-Aktien könnten in eine neue Phase eintreten. Nach einer langen Zeit von klinischer Unsicherheit, Cash-Burn-Konzepten und ungleichmäßiger Stimmung glaubt JPMorgan-Analystin Jessica Fye, dass viele der größten Namen im Sektor sich zu etablierten und finanziell dauerhaften Unternehmen entwickeln. Sie sieht den großen Biotech-Gruppe "broadly at an inflection point", wobei eine zunehmende Anzahl von Biotech-Unternehmen ihre Pipeline-Erfolge in 'durable, profitable commercial franchises' umwandelt. Fye glaubt, dass mehrere wichtige Trends gleichzeitig innerhalb des Gruppen entwickeln, einschließlich verbesserten Rentabilität, breiterer kommerzieller Diversifizierung, einer kontinuierlichen Flut klinischer Katalysatoren und weiteren Geschäftsentwicklungsaktivitäten. Sie glaubt auch, dass der Sektor weitere Deal-Making-Aktivität in den kommenden Quartalen erleben könnte, was möglicherweise ein günstiges Umfeld für große Biotech-Aktien schaffen würde.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Alnylam Pharmaceuticals, Inc. (ALNY) hat eine Partnerschaft mit der Firma Inceptive Nucleics, Inc., einem Unternehmen für künstliche Intelligenz-getriebene Biotechnologie, geschlossen. Der Wert des Deals liegt bei etwa 2 Milliarden Dollar. Durch die Zusammenarbeit sollen Alnylams Expertise in RNA-Interferenz-Therapeutika mit Inceptives AI-Fähigkeiten kombiniert werden, um die Entwicklung von Nukleinsäure-basierten Medikamenten zu beschleunigen. Alnylam erhält Zugang zu Inceptives AI-Experten und Talenten, einschließlich des CEO Jakob Uszkoreit, einem Mitentwickler der Transformer-Architektur.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Alnylam Pharmaceuticals (ALNY) hat einen Vertrag über bis zu 2 Milliarden US-Dollar mit Inceptive Nucleics abgeschlossen, um generative AI-Modelle zur Beschleunigung der Entwicklung von RNAi-Therapeutika einzusetzen. Inceptive Nucleics wird 30 Millionen US-Dollar im Voraus erhalten, einschließlich Bargeld und Inceptive-Aktien.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Jakob UszkoreitInceptive LogoAlnylam OfficeInceptive OfficeAlnylam B-Roll − Kooperation ist wertvoll bis zu 2 Milliarden US-Dollar mit einer Vorauszahlung von 30 Millionen US-Dollar − − Partnerschaft kombiniert Alnylams RNAi-Plattform und mehr als 20 Jahre proprietäre Daten mit Inceptives Grundmodellen und AI-Expertise, um Fortschritte in der rationellen Arzneimittelentwicklung zu katalysieren und zu beschleunigen – − Partnerschaft soll die Zeiträume beschleunigen und innovative Oligonukleotid-Designs freigeben − CAMBRIDGE, Mass. & PALO ALTO, Kalifornien, 3. Juni 2026–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), der führende RNAi-Therapeutika-Anbieter, und Inceptive Nucleics, Inc., das Grundmodelle des Lebens aufbaut, haben heute eine strategische Kooperationsvereinbarung zur Beschleunigung der therapeutischen Innovation bekannt gegeben. Die Kooperation ist wertvoll bis zu 2 Milliarden US-Dollar mit einer Vorauszahlung von 30 Millionen US-Dollar, einschließlich Bargeld und dem Kauf von Inceptives Aktien. Inceptive ist berechtigt, weitere Zahlungen aufgrund der Erfüllung präklinischer, regulatorischer und kommerzieller Verkaufsmilestones zu erhalten. Durch die Kombination von Inceptives generativen AI-Modellen mit Alnylams R&D-Motor soll Alnylam die Entdeckung neuer RNAi-Therapeutika beschleunigen, während es ambitionierte Pipeline-Erweiterungsziele als Teil seiner Alnylam 2030-Strategie verfolgt. "Wir sind begeistert, Inceptive zu unterstützen, um die Grenzen der RNA-Medikamentenentdeckung zu erweitern", sagte Yvonne Greenstreet, M.D., Chief Executive Officer von Alnylam. "Inceptive steht als eine der visionärsten Unternehmen an der Schnittstelle zwischen AI und Biologie hervor. Es wird von Pionieren der AI-Revolution geführt und getrieben durch ein ambitioniertes Ziel, die RNA-Medikamentenentwicklung grundlegend zu revolutionieren. Zusammen haben wir eine außergewöhnliche Gelegenheit, transformative Medikamente mit einer Geschwindigkeit, Kreativität und Sophistikation zu schaffen, die bislang nicht möglich war."